Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Skrgat (Golnik, Slovenia), P. Girandon Sušanj (Golnik, Slovenia), U. Bidovec Stojkovic (Golnik, Slovenia), P. Korošec (Golnik, Slovenia). Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma. 1132

Member's Comments

No comment yet.

Related content which might interest you: Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Anti-IgE treatment in children with severe intrinsic asthma Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Serum Interleukin (IL)-6 levels in patients with severe asthma disease is associated with blood eosinophilia Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020